Background / Aim. The availability of thrombopoietin receptor agonists
(TPO-RA) for the treatment of primary immune thrombocytopenia (ITP) over the
last decade has transformed its management. The aim of this study was to
assess the efficacy of TPO-RA in adults with chronic ITP treated in the
University Clinical Centre of Serbia. Methods. A total of 28 adult ITP
patients (10 males; 18 females) given eltrombopag and/or romiplostim were
enrolled in the study. Data on demographic characteristics, ITP duration,
previous therapeutic modalities, comorbidities, concomitant therapy,
indications for TPO-RA, bleeding episodes, TPO-RA doses, adverse events and
response rates were collected from the patients? medical records. TPO-RAs
were administered: (a) in patients with chronic refractory ITP; (b) when
splenectomy was contraindicated/unfeasible; (c) as preparation for
splenectomy. A favourable treatment response was defined as a stable
platelet count ? 50x109/L. Results. Twenty two (78.57%) and 14 (50.0%)
subjects were treated with eltrombopag and romiplostim, respectively. A good
treatment response (GTR) was achieved in 81.8% of the patients receiving
eltrombopag and in 71.4% of those treated with romiplostim. The
non-responders to eltrombopag (4 patients) and those who had lost their
response to eltrombopag (4 patients) were switched to romiplostim. Six of
them achieved a GTR. At the time of TPO-RA initiation, 46.4% of the patients
used concomitant ITP therapy which was ceased in all those with a GTR. The
following adverse effects of TPO-RA were registered: transaminitis and
transient ischemic attack for eltrombopag - one patient each, and pulmonary
embolism in one romiplostim treated patient. Conclusion. Our study showed
that TPO-RAs are an effective and safe treatment option, since the majority
of patients achieved stable remission without bleeding episodes.